SCHEMBL971982

SCHEMBL971982

CNC(C)(C)CC(=O)OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.43
HSD17B10 Q99714 4/20 0.40
MGAM O43451 1/20 0.40
GAA P10253 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
TET2 Q6N021 1/20 0.38
RECQL P46063 2/20 0.37
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
CA12 O43570 2/20 0.32
CA14 Q9ULX7 2/20 0.32
CA2 P00918 1/20 0.32
LMNA P02545 3/20 0.32
KDM4E B2RXH2 1/20 0.32
HPGD P15428 1/20 0.32
ALDH1A1 P00352 2/20 0.31
MAPT P10636 1/20 0.31
HTT P42858 1/20 0.31
USP2 O75604 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11499797 0.98 TSHR (0.42) TSHRHSD17B10MGAMGAASI
SCHEMBL9304443 0.79 GAA (0.52) HSD17B10MGAMGAASIMGAM2
SCHEMBL15621423 0.76 MGAM (0.42) TSHRHSD17B10MGAMGAASI
SCHEMBL15621164 0.76 TET2 (0.45) TSHRHSD17B10MGAMGAASI
SCHEMBL167149 0.76
SCHEMBL667630 0.76 TSHR (0.50) TSHRHSD17B10MGAMGAASI
SCHEMBL9098441 0.75 TSHR (0.39) TSHRHSD17B10MGAMGAASI
SCHEMBL7109527 0.75 TSHR (0.40) TSHRHSD17B10MGAMGAASI
SCHEMBL9098443 0.75 TSHR (0.39) TSHRHSD17B10MGAMGAASI
SCHEMBL7047649 0.74 HMGCR (0.50) TSHRHSD17B10MGAMGAASI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024097355-A1 DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS VICINITAS THERAPEUTICS, INC. (US) 2024-05-10 WO disclosed
US-20230287021-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING PROTEGO BIOPHARMA, INC. 2023-09-14 US disclosed
US-20230287021-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING PROTEGO BIOPHARMA, INC. 2023-09-14 US disclosed
EP-4097092-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING Protego Biopharma, Inc. (US) 2022-12-07 EP disclosed
CN-115298168-A Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding 普罗泰格生物制药公司 2022-11-04 CN disclosed
WO-2021154842-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING PROTEGO BIOPHARMA, INC. (US) 2021-08-05 WO disclosed
WO-2021154842-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING PROTEGO BIOPHARMA, INC. (US) 2021-08-05 WO disclosed
US-20110009392-A1 GAMMA SECRETASE MODULATORS SCHERING CORPORATION 2011-01-13 US disclosed
US-4216216-A TREATING MIGRAINE HEADACHES, ANTI-HISTAMINES HOECHST AKTIENGESELLSCHAFT (DE) 1980-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230287021-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING TTR, TTPA, TNNC1 TSHR 2387/4885HSD17B10 2869/4885MGAM 943/4885
US-20110009392-A1 GAMMA SECRETASE MODULATORS BACE1, BACE2, PSEN1 TSHR 4286/4885HSD17B10 2915/4885MGAM 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.